AMLODIPINE FORMULATIONS
First Claim
Patent Images
1. A suspension comprising amlodipine benzoate particles having a D50 value between about 5 μ
- m and about 40 μ
m, the suspension made by the process comprising;
(i) providing an aqueous mixture of an amlodipine salt that is more soluble in aqueous media than amlodipine benzoate;
(ii) adding sodium benzoate to the aqueous mixture to form a first mixture; and
(iii) subjecting the first mixture to ultrasonic agitation thereby forming a second mixture comprising amlodipine benzoate.
7 Assignments
0 Petitions
Accused Products
Abstract
Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
4 Citations
30 Claims
-
1. A suspension comprising amlodipine benzoate particles having a D50 value between about 5 μ
- m and about 40 μ
m, the suspension made by the process comprising;(i) providing an aqueous mixture of an amlodipine salt that is more soluble in aqueous media than amlodipine benzoate; (ii) adding sodium benzoate to the aqueous mixture to form a first mixture; and (iii) subjecting the first mixture to ultrasonic agitation thereby forming a second mixture comprising amlodipine benzoate. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)
- m and about 40 μ
-
29. A suspension comprising amlodipine benzoate particles having a D50 value between about 5 μ
- m and about 40 μ
m, the suspension made by the process comprising;(i) providing an aqueous mixture of an amlodipine salt that is more soluble in aqueous media than amlodipine benzoate; (ii) adding sodium benzoate to the aqueous mixture to form a first mixture; and (iii) subjecting the first mixture to ultrasonic agitation thereby forming a second mixture comprising amlodipine benzoate, wherein the suspension comprises; (i) amlodipine benzoate in an amount corresponding to about 0.8 mg/ml to about 1.2 mg/ml of amlodipine free base; (ii) a citrate buffer in an amount between about 1 mM and about 5 mM; (iii) about 0.1 mg/ml to about 5.0 mg/ml sodium benzoate; (iv) about 0.1 mg/ml to about 1.0 mg/ml of silicon dioxide; (v) about 3 mg/ml to about 10 mg/ml of hydroxypropyl methylcellulose; (vi) about 0.1 mg/ml to about 1.0 mg/ml of simethicone; (vii) about 0.1 mg/ml to about 2 mg/ml of polysorbate 80; and (viii) water.
- m and about 40 μ
-
30. A suspension comprising amlodipine benzoate particles having a D50 value between about 5 μ
- m and about 40 μ
m, the suspension made by the process comprising;(i) providing an aqueous mixture of an amlodipine salt that is more soluble in aqueous media than amlodipine benzoate; (ii) adding sodium benzoate to the aqueous mixture to form a first mixture; and (iii) subjecting the first mixture to ultrasonic agitation thereby forming a second mixture comprising amlodipine benzoate, wherein the suspension comprises; (i) amlodipine benzoate in an amount corresponding to about 1.0 mg/ml of amlodipine free base; (ii) about 3 mM of a citrate buffer; (iii) about 0.1 mg/ml to about 5.0 mg/ml sodium benzoate; (iv) about 0.5 mg/ml of silicon dioxide; (v) about 7.5 mg/ml of hydroxypropyl methylcellulose; (vi) about 0.15 mg/ml of simethicone; (vii) about 1.0 mg/ml of polysorbate 80; and (viii) water, wherein the suspension is stable at about 5±
5°
C. for at least 12 months.
- m and about 40 μ
Specification